BR0302523A - Stable pharmaceutical composition for administration of hiv protease inhibitors and process for obtaining concentrated pharmaceutical composition for administration of hiv protease inhibitors - Google Patents

Stable pharmaceutical composition for administration of hiv protease inhibitors and process for obtaining concentrated pharmaceutical composition for administration of hiv protease inhibitors

Info

Publication number
BR0302523A
BR0302523A BR0302523-3A BR0302523A BR0302523A BR 0302523 A BR0302523 A BR 0302523A BR 0302523 A BR0302523 A BR 0302523A BR 0302523 A BR0302523 A BR 0302523A
Authority
BR
Brazil
Prior art keywords
administration
protease inhibitors
hiv protease
pharmaceutical composition
stable
Prior art date
Application number
BR0302523-3A
Other languages
Portuguese (pt)
Inventor
Ogari De Castro Dr Pacheco
Elisa Mannochio De Souza Russo
Valter Freire Torres Russo
Original Assignee
Cristalia Prod Quimicos Farm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cristalia Prod Quimicos Farm filed Critical Cristalia Prod Quimicos Farm
Priority to BR0302523-3A priority Critical patent/BR0302523A/en
Priority to PCT/BR2004/000119 priority patent/WO2005007070A2/en
Publication of BR0302523A publication Critical patent/BR0302523A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA ESTáVEL PARA ADMINISTRAçãO DE INIBIDORES DA HIV PROTEASE E PROCESSO DE OBTENçãO DE COMPOSIçãO FARMACêUTICA CONCENTRADA PARA A ADMINISTRAçãO DE INIBIDORES DA HIV PROTEASE". A presente invenção descreve uma composição farmacêutica solúvel estável para a administração de inibidores da HIV protease. Mais especificamente a composição compreende uma solução de um ou dois inibidores da HIV protease em uma combinação de solventes orgânicos farmacêuticos adequados, um surfatante e um ampliador de biodisponibilidade. é descrito também um processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da HIV protease. A composição da presente invenção é adequada a obtenção de soluções orais para a administração de drogas ativas e ao encapsulamento em cápsulas de gelatina dura ou cápsulas de gelatina mole."STABLE PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION OF HIV PROTEASE INHIBITORS AND CONCENTRATED PHARMACEUTICAL COMPOSITION PROCESS FOR ADMINISTRATION OF HIV PROTEASE INHIBITORS". The present invention describes a stable soluble pharmaceutical composition for the administration of HIV protease inhibitors. More specifically the composition comprises a solution of one or two HIV protease inhibitors in a combination of suitable pharmaceutical organic solvents, a surfactant and a bioavailability enhancer. Also described is a process for obtaining concentrated pharmaceutical compositions for the administration of HIV protease inhibitors. The composition of the present invention is suitable for obtaining oral solutions for administration of active drugs and encapsulation in hard gelatin capsules or soft gelatin capsules.

BR0302523-3A 2003-07-23 2003-07-23 Stable pharmaceutical composition for administration of hiv protease inhibitors and process for obtaining concentrated pharmaceutical composition for administration of hiv protease inhibitors BR0302523A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BR0302523-3A BR0302523A (en) 2003-07-23 2003-07-23 Stable pharmaceutical composition for administration of hiv protease inhibitors and process for obtaining concentrated pharmaceutical composition for administration of hiv protease inhibitors
PCT/BR2004/000119 WO2005007070A2 (en) 2003-07-23 2004-07-19 Stable pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR0302523-3A BR0302523A (en) 2003-07-23 2003-07-23 Stable pharmaceutical composition for administration of hiv protease inhibitors and process for obtaining concentrated pharmaceutical composition for administration of hiv protease inhibitors

Publications (1)

Publication Number Publication Date
BR0302523A true BR0302523A (en) 2005-04-05

Family

ID=37719699

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0302523-3A BR0302523A (en) 2003-07-23 2003-07-23 Stable pharmaceutical composition for administration of hiv protease inhibitors and process for obtaining concentrated pharmaceutical composition for administration of hiv protease inhibitors

Country Status (2)

Country Link
BR (1) BR0302523A (en)
WO (1) WO2005007070A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2012010942A2 (en) 2010-07-22 2012-01-26 Lupin Limited Novel pharmaceutical composition(s) of hiv protease inhibitor(s)
WO2019130341A1 (en) * 2017-12-26 2019-07-04 Hetero Labs Limited Capsule compositions comprising lopinavir and ritonavir
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
GB201907305D0 (en) * 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition

Also Published As

Publication number Publication date
WO2005007070A2 (en) 2005-01-27
WO2005007070A3 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
HK1080364A1 (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability
MA29744B1 (en) SOLID DOSAGE FORMULATIONS OF MEDICAMENTS HAVING IMPROVED ORAL ADSORPTION
CO5560580A2 (en) FORMULATIONS OF SUCRALOSE TO DISPENSE FLAVORABLE FLAVORS
EA201270738A1 (en) MODULATORS OF PHARMACOKINETIC PROPERTIES OF MEDICINES
HUP0203451A2 (en) Pharmaceutical compositions of anti-tubercular drugs and process for their preparation
WO2005065646A3 (en) Novel drug compositions and dosage forms
CA2414063A1 (en) Highly concentrated stable meloxicam solutions
MXPA03011538A (en) Medicinal compositions.
AR037490A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS, PROCESS FOR PREPARATION, KIT FOR THE TREATMENT OF OBESITY AND USE OF SUCH COMPOSITIONS IN THE DEVELOPMENT OF MEDICINES
BRPI0415053B8 (en) p-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same
AR027360A1 (en) PHARMACEUTICAL COMPOSITION
BRPI0510694A (en) pharmaceutical compositions comprising concentrated soft gelatin encapsulated active ingredients
BR0302523A (en) Stable pharmaceutical composition for administration of hiv protease inhibitors and process for obtaining concentrated pharmaceutical composition for administration of hiv protease inhibitors
NO950134L (en) Formulations for orally administered pharmaceutical agents
BR0202252A (en) Stable soluble pharmaceutical composition for administration of hiv protease inhibitors and process for obtaining concentrated pharmaceutical compositions for administration of hiv protease inhibitors
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
BR0312004A (en) Transdermal Aerosol Compositions
HUP0105359A2 (en) Benzamide derivatives and drugs containing the same
EA200100725A3 (en) Benzothiadiazine compounds, a process for their preparation and pharmaceutical compositions containing them
AR030715A1 (en) FLAVORING SYSTEMS FOR PHARMACEUTICAL COMPOSITIONS AND METHODS TO MAKE SUCH COMPOSITIONS
BR0115506A (en) Pharmaceutical compositions having an antidiabetic action, and process for their preparation
BR0213463A (en) Macrolide-containing pharmaceutical compositions
BR0302424A (en) Pharmaceutical composition with enhanced bioavailability suitable for oral administration of retroviral protease inhibitors. process for preparing a concentrated pharmaceutical composition containing retroviral protease inhibitor
EA200501366A1 (en) MEDICINE
UY27017A1 (en) HYDROLYTICALLY UNSTABLE COMPOSITIONS

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)